title: Zuclopenthixol: a new generation of antipsychotic drugs. An open clinical trial.
abstract: Fifteen patients (20-49 years of age) with mania or acute psychosis were treated with zuclopenthixol acetate (Clopixol, Acuphase). One injection of 75-100 mg produced significant amelioration of psychotic symptoms with minimal side effects. The duration of action of the drug was found to be about 72 hours.
authors.affiliation: College of Medicine, Arabian Gulf University, Manama, Bahrain.
authors.forename: A M
authors.initials: AM
authors.lastname: Matar
authors.forename: M
authors.initials: M
authors.lastname: Abdel-Mawgoud
authors.forename: S
authors.initials: S
authors.lastname: Skov
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents; D003006:Clopenthixol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology
chemical_list: D014150:Antipsychotic Agents; C060342:clopenthixol acetate ester; D003006:Clopenthixol